Skip to content

R3 Acetabular Hip system in patients with degenerative joint disease.

A prospective, multicenter, non-randomized study to evaluate the safety and efectiveness of the R3 Acetabular Hip System in patients with degenerative joint disease.

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12608000234314
Enrollment
70
Registered
2008-05-07
Start date
2009-02-25
Completion date
2012-05-24
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study will investigate functional performance of the R3 Acetabular System, compared to a previous design, the Reflection System. Both systems are under approval by the Therapeutic Goods Administration, however the functional performance of the R3 Acetabular System compared to other systems has not yet been investigated.

Interventions

The R3 Acetabular System is designed with large ball heads providing increased range of motion and greater stability. This can significantly reduce the risk of hip dislocation, which is a crucial factor in the long term success of an implant. CoCr is an alloy of cobalt chrome with improved properties that make it suitable for use against ultra high molecular weight polyethylene surfaces in opposing friction couples.the length of the study is upto 5 years.

Sponsors

Smith & Nephew
Lead SponsorCommercial sector/Industry

Study design

Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1.Patient is of legal age to consent and skeletally mature. 2. Patient requires primary total hip arthroplasty due to non-inflammatory degenerative joint disease (e.g. osteoarthritis, traumatic arthritis, avascular necrosis, and dysplasia/DDH). 3.Patient has met an acceptable preoperative medical clearance and is free from or treated for cardiac, pulmonary, hematological, etc., conditions that would pose excessive operative risk. 4 The patient will be available for follow-up throughout the duration of the study.

Exclusion criteria

Subjects with any of the following characteristics must be excluded from participation in the study. 1.Patient has active infection or sepsis (treated or untreated) 2.Patient has any vascular insufficiency, muscular atrophy, or neuromuscular disease severe enough to compromise implant stability or postoperative recovery. 3.Patient is female of child-bearing age and not taking contraceptive precautions 4.Patient has inadequate bone stock to support the device (e.g. severe osteopenia, family history of severe osteoporosis or osteopenia) 5.Patient has inflammatory joint disease (e.g. rheumatoid arthritis) 6.Patient has known moderate to severe renal insufficiency. 6.Patient has a known or suspected metal sensitivity. 7.Patient is immunosuppressed with diseases such as AIDS or receiving high doses of corticosteroids. 8.Patient has an emotional or neurological condition that would pre-empt their ability or unwillingness to participate in the study including mental illness, mental retardation, or drug, alcohol abuse. 9.Patient is severely overweight.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026